Abstract
Icotinib is a novel and selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) for oral usage. Adjuvant therapy with icotinib has been confirmed to be associated with the improvement of DFS among patients with EGFR-mutant non-small-cell lung cancer (NSCLC) in several studies. However, the clinical benefit of neoadjuvant icotinib combined with chemotherapy for EGFR-mutant NSCLC remains unknown. This is the first trial evaluating the efficacy and safety of icotinib plus chemotherapy as neoadjuvant therapy for patients with stage II-IIIB EGFR-mutant NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
